Condition (MeSH)
Acute Generalized Exanthematous Pustulosis
ClinicalTrials.gov lists 3 trials for Acute Generalized Exanthematous Pustulosis or a narrower condition beneath it. AI Labs Group S.L has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
2 sections measured, none recorded · 1 not measured yet · 1 not computed
3 of the 3 trials are tagged with Acute Generalized Exanthematous Pustulosis itself; the rest are tagged with a narrower condition beneath it.
When did Acute Generalized Exanthematous Pustulosis trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2014 | 2 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Acute Generalized Exanthematous Pustulosis trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 3 |
How many Acute Generalized Exanthematous Pustulosis trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Acute Generalized Exanthematous Pustulosis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AI Labs Group S.L | 1 |
Which publications cover Acute Generalized Exanthematous Pustulosis? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Severe cutaneous adverse reactions to drugs. | Lancet (London, England) | 2017 | Yes |
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Acute generalized exanthematous pustulosis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Acute generalized exanthematous pustulosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Acute generalized exanthematous pustulosis | Annual incidence | <1 / 1 000 000 | Israel | Not stated | Exact |
| Acute generalized exanthematous pustulosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Acute generalized exanthematous pustulosis | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Acute generalized exanthematous pustulosis | 293173 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Acute generalized exanthematous pustulosis | 293173 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.